Ironwood Pharmaceuticals (IRWD) Gains from Investment Securities (2016 - 2025)
Ironwood Pharmaceuticals (IRWD) has disclosed Gains from Investment Securities for 17 consecutive years, with $3000.0 as the latest value for Q4 2025.
- Quarterly Gains from Investment Securities rose 100.37% to $3000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9000.0 through Dec 2025, up 88.0% year-over-year, with the annual reading at $1.1 million for FY2025, 74.87% down from the prior year.
- Gains from Investment Securities hit $3000.0 in Q4 2025 for Ironwood Pharmaceuticals, up from -$7000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $4.1 million in Q2 2021 to a low of -$4.1 million in Q1 2021.
- Historically, Gains from Investment Securities has averaged $232562.5 across 5 years, with a median of -$13000.0 in 2023.
- Biggest YoY gain for Gains from Investment Securities was 139750.0% in 2021; the steepest drop was 25581.25% in 2021.
- Year by year, Gains from Investment Securities stood at $2.8 million in 2021, then decreased by 20.69% to $2.2 million in 2022, then crashed by 90.11% to $219000.0 in 2023, then tumbled by 470.78% to -$812000.0 in 2024, then surged by 100.37% to $3000.0 in 2025.
- Business Quant data shows Gains from Investment Securities for IRWD at $3000.0 in Q4 2025, -$7000.0 in Q3 2025, and -$812000.0 in Q4 2024.